Abstract
The kinase inhibitor tucatinib (Tukysa) has been approved to treat advanced unresectable or metastatic HER2-positive breast cancer. The drug is given orally in combination with trastuzumab (Herceptin) and capecitabine (Xeloda). It is not first-line therapy.Sacituzumab govitecan-hziy (Trodelvy) has been approved to treat triple-negative breast cancer that has metastasized. It is a targeted therapy monoclonal antibody given by IV infusion. The drug carries a boxed warning for risk of severe neutropenia and severe diarrhea.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
